Takeda expands patient assistance program in U.S.
DEERFIELD, Ill. — Takeda Pharmaceuticals on Thursday announced that it would be expanding its Help At Hand patient assistance program for patients in the United States.
The expansion will allow patients whose income is at 400% of the federal poverty level to apply for discounted or no-cost medicine under the program, which currently includes 11 of the company’s drugs. Under the expansion, a family of four whose household income is about $100,000 is now eligible for the prescription drug program.
"We have expanded this program to allow more U.S. patients to gain access to Takeda medicines that can potentially improve their health,” Takeda Pharmaceuticals U.S.A president Ramona Sequeira said. “Every day, we’re placing the needs of patients at the center of what we do around the world. This program expansion in the U.S. is one more way we’re showing patients we’re focused on their needs.”
FDA expands indication for Teva’s ProAir RespiClick
SILVER SPRING, Md. — The Food and Drug Administration on Friday approved Teva’s ProAir RespiClick (albuterol sulfate) inhalation powder to treat or prevent bronchospasm in children aged 4 to 11 years. The drug had previously been approved for the same indication in patients older than 12.
The drug is the only breath-activated multi-dose short-acting beta agonist, inhaler in the U.S., Teva said.
“We are very pleased with the FDA’s decision to expand the indication of ProAir RespiClick for the treatment of patients as young as four years of age,” Teva SVP global respiratory research and development Dr. Tushar Shah said. “The availability of this treatment option for younger patients is a demonstration of Teva’s commitment to optimizing respiratory therapies through the development of new delivery systems that help address needs in the marketplace.”
Diplomat to acquire TNH Advanced Specialty Pharmacy
FLINT, Mich. — Diplomat Pharmacy on Thursday announced the planned acquisition of Valley Campus Pharmacy, which does business as TNH Advanced Specialty Pharmacy (TNH). The deal will see the nation’s largest independent specialty pharmacy acquiring the seven-year-old oncology-focused company for $75 million, a mixture of cash and about 328,000 shares of Diplomat stock.
“This partnership opens new prescriber relationships and growth opportunities with TNH's market concentration in California and Texas. Further, Diplomat recently added a licensed Texas facility to enable brick and mortar presence for the State of Texas Medicaid program,” Diplomat CEO and chairman Phil Hagerman said. “According to a 2014 report by the American Association of Medicaid Pharmacy Administrators, Texas Medicaid serves 3.7 million patients. Our combined resources will make us stronger and more unique within the specialty services industry."
TNH currently dispenses 20 limited distribution drugs, many of which are oncology drugs, and it is one of the country’s fastest growing independent pharmacies, posting revenues of about $400 million in 2015, up from $240 million in 2014. In addition, TNH has relationships with some 1,700 referring prescribers and a platform called TNH Live, which allows for transparency between prescribers, pharma companies and payers with its real-time data capabilities.
“We are proud and excited to join the Diplomat family of companies,” TNH CEO Avo Minasyan said. “Diplomat's dedication to high-touch medication management programs for patients with complex chronic diseases echo our own. Together, we will work with patients, prescribers, and pharmaceutical manufacturers to enhance the entire care experience.”
Diplomat said it expects to close the transaction in the next 30 to 60 days, with plans to leave key management team members and co-founders in place.
Loading Post Please Wait...